AmplifyBio, a preclinical contract research organization (CRO), intends to build on discovery and characterization capabilities with the purchase of assets, including a site and a team of TCR-based drug development experts from PACT Pharma late last year.
In a statement, the company said that it has initiated additional partnership agreements that are designed to enhance their ability to perform single-cell genotype and phenotype assessment of CAR-Ts and other cell-based therapies, providing more granularity to product characterization, especially in context with drug potency.
